CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porters five forces analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in prevalence of cancer diseases
3.5.1.2.Rise in geriatric population
3.5.1.3.Growth in awareness among consumers regarding cancer immunotherapy
3.5.1.4.Increase in expenditure for the healthcare sector
3.5.2.Restraints
3.5.2.1.Risk of allergic reaction and limitations of the cancer immunotherapy treatment
3.5.2.2.Stringent government regulations
3.5.3.Opportunity
3.5.3.1.Increasing research and development in cancer immunotherapy
3.5.4.Impact analysis
3.6.Impact analysis of COVID-19 on the cancer immunotherapy market
CHAPTER 4:CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGY TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Monoclonal antibodies
4.2.1.Market size and forecast, by region
4.2.2.Market analysis, by country
4.3.Cytokines & Immunomodulators
4.3.1.Market size and forecast, by region
4.3.2.Market analysis, by country
4.4.Others
4.4.1.Market size and forecast, by region
4.4.2.Market analysis, by country
CHAPTER 5:CANCER IMMUNOTHERAPY MARKET, BY APPLICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Lung Cancer
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Breast Cancer
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Colorectal Cancer
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
5.5.Melanoma
5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country
5.6.Prostate Cancer
5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country
5.7.Head & Neck Cancer
5.7.1.Market size and forecast, by region
5.7.2.Market analysis, by country
5.8.Others
5.8.1.Market size and forecast, by region
5.8.2.Market analysis, by country
CHAPTER 6:CANCER IMMUNOTHERAPY MARKET, BY END USER
6.1.Overview
6.1.1.Market size and forecast
6.2.Hospitals
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Cancer Research Centers
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
6.4.Clinics
6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country
CHAPTER 7:CANCER IMMUNOTHERAPY MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.North America market size and forecast, by technologies type
7.2.2.North America market size and forecast, by application
7.2.3.North America market size and forecast, by end user
7.2.4.North America market size and forecast, by country
7.2.5.U.S.
7.2.5.1.U.S. market size and forecast, by technologies type
7.2.5.2.U.S. market size and forecast, by application
7.2.5.3.U.S. market size and forecast, by end user
7.2.6.Canada
7.2.6.1.Canada market size and forecast, by technologies type
7.2.6.2.Canada market size and forecast, by application
7.2.6.3.Canada market size and forecast, by end user
7.2.7.Mexico
7.2.7.1.Mexico market size and forecast, by technologies type
7.2.7.2.Mexico market size and forecast, by application
7.2.7.3.Mexico market size and forecast, by end user
7.3.Europe
7.3.1.Europe market size and forecast, by technologies type
7.3.2.Europe market size and forecast, by application
7.3.3.Europe market size and forecast, by end user
7.3.4.Europe market size and forecast, by country
7.3.5.Germany
7.3.5.1.Germany market size and forecast, by technologies type
7.3.5.2.Germany market size and forecast, by application
7.3.5.3.Germany market size and forecast, by end user
7.3.6.France
7.3.6.1.France market size and forecast, by technologies type
7.3.6.2.France market size and forecast, by application
7.3.6.3.France market size and forecast, by end user
7.3.7.UK
7.3.7.1.UK market size and forecast, by technologies type
7.3.7.2.UK market size and forecast, by application
7.3.7.3.UK market size and forecast, by end user
7.3.8.Italy
7.3.8.1.Italy market size and forecast, by technologies type
7.3.8.2.Italy market size and forecast, by application
7.3.8.3.Italy market size and forecast, by end user
7.3.9.Spain
7.3.9.1.Spain market size and forecast, by technologies type
7.3.9.2.Spain market size and forecast, by application
7.3.9.3.Spain market size and forecast, by end user
7.3.10.Rest of Europe
7.3.10.1.Rest of Europe market size and forecast, by technologies type
7.3.10.2.Rest of Europe market size and forecast, by application
7.3.10.3.Rest of Europe market size and forecast, by end user
7.4.Asia-Pacific
7.4.1.Asia-Pacific market size and forecast, by technologies type
7.4.2.Asia-Pacific market size and forecast, by application
7.4.3.Asia-Pacific market size and forecast, by end user
7.4.4.Asia-Pacific market size and forecast, by country
7.4.5.Japan
7.4.5.1.Japan market size and forecast, by technologies type
7.4.5.2.Japan market size and forecast, by application
7.4.5.3.Japan market size and forecast, by end user
7.4.6.China
7.4.6.1.China market size and forecast, by technologies type
7.4.6.2.China market size and forecast, by application
7.4.6.3.China market size and forecast, by end user
7.4.7.India
7.4.7.1.India market size and forecast, by technologies type
7.4.7.2.India market size and forecast, by application
7.4.7.3.India market size and forecast, by end user
7.4.8.Rest of Asia-Pacific
7.4.8.1.Rest of Asia-Pacific market size and forecast, by technologies type
7.4.8.2.Rest of Asia-Pacific market size and forecast, by application
7.4.8.3.Rest of Asia-Pacific market size and forecast, by end user
7.5.LAMEA
7.5.1.LAMEA market size and forecast, by technologies type
7.5.2.LAMEA market size and forecast, by application
7.5.3.LAMEA market size and forecast, by end user
7.5.4.LAMEA market size and forecast, by country
7.5.5.Latin America
7.5.5.1.Latin America market size and forecast, by technologies type
7.5.5.2.Latin America market size and forecast, by application
7.5.5.3.Latin America market size and forecast, by end user
7.5.6.Middle East
7.5.6.1.Middle East market size and forecast, by technologies type
7.5.6.2.Middle East market size and forecast, by application
7.5.6.3.Middle East market size and forecast, by end user
7.5.7.Africa
7.5.7.1.Africa market size and forecast, by technologies type
7.5.7.2.Africa market size and forecast, by application
7.5.7.3.Africa market size and forecast, by end user
CHAPTER 8:COMPANY PROFILES
8.1.AMGEN, INC.
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.2.ASTRAZENECA, PLC.
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments
8.3.BAYER AG
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.3.6.Key strategic moves and developments
8.4.BRISTOL-MYERS SQUIBB COMPANY
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments
8.5.ELI LILY AND COMPANY
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments
8.6.F. HOFFMANN-LA ROCHE LTD (GENENTECH, INC.)
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments
8.7.JOHNSON & JOHNSON (Janssen Global Services, LLC)
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments
8.8.MERCK KGAA
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.NOVARTIS AG
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments
8.10.PFIZER INC.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments
LIST OF TABLES
TABLE 01.GLOBAL CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGY TYPE, 20202030 ($MILLION)
TABLE 02.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR TEMPERATURE PATCH, BY REGION, 20202030 ($MILLION)
TABLE 03.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR CYTOKINES AND IMMUNOMODULATORS, BY REGION, 20202030 ($MILLION)
TABLE 04.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR OTHERS, BY REGION, 20202030 ($MILLION)
TABLE 05.GLOBAL CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030 ($MILLION)
TABLE 06.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR HEALTHCARE, BY REGION, 20202030 ($MILLION)
TABLE 07.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR BREAST CANCER, BY REGION, 20202030 ($MILLION)
TABLE 08.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR COLORECTAL CANCER, BY REGION, 20202030 ($MILLION)
TABLE 09.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR MELANOMA, BY REGION, 20202030 ($MILLION)
TABLE 10.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR PROSTATE CANCER, BY REGION, 20202030 ($MILLION)
TABLE 11.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR HEAD & NECK CANCER, BY REGION, 20202030 ($MILLION)
TABLE 12.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR OTHERS, BY REGION, 20202030 ($MILLION)
TABLE 13.GLOBAL CANCER IMMUNOTHERAPY MARKET, BY END USER, 20202030 ($MILLION)
TABLE 14.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR HOSPITALS, BY REGION, 20202030 ($MILLION)
TABLE 15.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR CANCER RESEARCH CENTERS, BY REGION, 20202030 ($MILLION)
TABLE 16.GLOBAL CANCER IMMUNOTHERAPY MARKET FOR CLINICS, BY REGION, 20202030 ($MILLION)
TABLE 17.CANCER IMMUNOTHERAPY MARKET, BY REGION, 20202030, ($MILLION)
TABLE 18.NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 19.NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 20.NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY END USE, 20202030, ($MILLION)
TABLE 21.NORTH AMERICA CANCER IMMUNOTHERAPY MARKET, BY COUNTRY, 20202030, ($MILLION)
TABLE 22.U.S. CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 23.U.S. CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 24.U.S. CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 25.CANADA CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 26.CANADA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 27.CANADA CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 28.MEXICO CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 29.MEXICO CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 30.MEXICO CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 31.EUROPE CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 32.EUROPE CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 33.EUROPE CANCER IMMUNOTHERAPY MARKET, BY END USE, 20202030, ($MILLION)
TABLE 34.EUROPE CANCER IMMUNOTHERAPY MARKET, BY COUNTRY, 20202030, ($MILLION)
TABLE 35.GERMANY CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 36.GERMANY CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 37.GERMANY CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 38.FRANCE CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 39.FRANCE CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 40.FRANCE CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 41.UK CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 42.UK CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 43.UK CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 44.ITALY CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 45.ITALY CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 46.ITALY CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 47.SPAIN CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 48.SPAIN CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 49.SPAIN CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 50.REST OF EUROPE CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 51.REST OF EUROPE CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 52.REST OF EUROPE CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 53.ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 54.ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 55.ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY END USE, 20202030, ($MILLION)
TABLE 56.ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY COUNTRY, 20202030, ($MILLION)
TABLE 57.JAPAN CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 58.JAPAN CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 59.JAPAN CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 60.CHINA CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 61.CHINA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 62.CHINA CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 63.INDIA CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 64.INDIA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 65.INDIA CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 66.REST OF ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 67.REST OF ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 68.REST OF ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 69.LAMEA CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 70.LAMEA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 71.LAMEA CANCER IMMUNOTHERAPY MARKET, BY END USE, 20202030, ($MILLION)
TABLE 72.LAMEA CANCER IMMUNOTHERAPY MARKET, BY COUNTRY, 20202030, ($MILLION)
TABLE 73.LATIN AMERICA CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 74.LATIN AMERICA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 75.LATIN AMERICA CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 76.MIDDLE EAST CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 77.MIDDLE EAST CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 78.MIDDLE EAST CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 79.AFRICA CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGIES TYPE, 20202030, ($MILLION)
TABLE 80.AFRICA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 20202030, ($MILLION)
TABLE 81.AFRICA CANCER IMMUNOTHERAPY MARKET, BY END USER, 2020-2030, ($MILLION)
TABLE 82.MEDTRONIC: COMPANY SNAPSHOT
TABLE 83.AMGEN: OPERATING SEGMENTS
TABLE 84.AMGEN: PRODUCT PORTFOLIO
TABLE 85.ASTRAZENECA: COMPANY SNAPSHOT
TABLE 86.ASTRAZENECA INC.: OPERATING SEGMENTS
TABLE 87.ASTRAZENECA INC.: PRODUCT PORTFOLIO
TABLE 88.BAYER : COMPANY SNAPSHOT
TABLE 89.BAYER : OPERATING SEGMENT
TABLE 90.BAYER : PRODUCT PORTFOLIO
TABLE 91.BMS: COMPANY SNAPSHOT
TABLE 92.BMS: PRODUCT PORTFOLIO
TABLE 93.ELI LILLY: COMPANY SNAPSHOT
TABLE 94.LILLY: OPERATING SEGMENTS
TABLE 95.ELI LILLY: PRODUCT PORTFOLIO
TABLE 96.ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 97.ROCHE: COMPANY SNAPSHOT
TABLE 98.ROCHE : OPERATING SEGMENTS
TABLE 99.ROCHE : PRODUCT PORTFOLIO
TABLE 100.ROCHE : KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 101.J&J: COMPANY SNAPSHOT
TABLE 102.J&J: OPERATING BUSINESS SEGMENTS
TABLE 103.J&J: PRODUCT PORTFOLIO
TABLE 104.J&J : KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 105.MERCK: COMPANY SNAPSHOT
TABLE 106.MERCK: OPERATING SEGMENTS
TABLE 107.MERCK: PRODUCT PORTFOLIO
TABLE 108.NOVARTIS: COMPANY SNAPSHOT
TABLE 109.NOVARTIS: OPERATING SEGMENT
TABLE 110.NOVARTIS : PRODUCT PORTFOLIO
TABLE 111.PFIZER: COMPANY SNAPSHOT
TABLE 112.PFIZER: OPERATING SEGMENT
TABLE 113.PFIZER: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.GLOBAL CANCER IMMUNOTHERAPY MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 20182021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 20182021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 20182021
FIGURE 06.HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 07.HIGH BARGAINING POWER OF BUYERS
FIGURE 08.HIGH THREAT OF SUBSTITUTES
FIGURE 09.HIGH THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR TEMPERATURE PATCH, BY COUNTRY, 2020 & 2030 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR CYTOKINES AND IMMUNOMODULATORS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR LUNG CANCER, BY COUNTRY, 2020 & 2030 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR BREAST CANCER, BY COUNTRY, 2020 & 2030 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2020 & 2030 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR MELANOMA, BY COUNTRY, 2020 & 2030 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2020 & 2030 (%)
FIGURE 21.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR HEAD & NECK CANCER, BY COUNTRY, 2020 & 2030 (%)
FIGURE 22.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 23.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 24.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR CANCER RESEARCH CENTERS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 25.COMPARATIVE ANALYSIS OF GLOBAL CANCER IMMUNOTHERAPY MARKET FOR CLINICS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 26.AMGEN: NET SALES, 20182020 ($MILLION)
FIGURE 28.AMGEN: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 29.ASTRAZENECA: NET SALES, 20182020 ($MILLION)
FIGURE 30.ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 31.ASTRAZENECA: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 32.BAYER : NET SALES, 20182020 ($MILLION)
FIGURE 33.BAYER: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 34.BAYER: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 35.BMS: NET SALES, 20182020 ($MILLION)
FIGURE 36.BMS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 37.ELI LILLY: NET SALES, 20182020 ($MILLION)
FIGURE 38.ELI LILLY: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 39.ELI LILLY: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 40.ROCHE: NET SALES, 20182020 ($MILLION)
FIGURE 41.ROCHE: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 42.ROCHE: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 43.J&J: NET SALES, 20182020 ($MILLION)
FIGURE 44.J&J: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 45.J&J: REVENUE SHARE BY REGION, 2020(%)
FIGURE 46.MERCK: NET SALES, 2018-2020 ($MILLION)
FIGURE 47.MERCK: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 48.MERCK: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 49.NOVARTIS: NET SALES, 20182020 ($MILLION)
FIGURE 50.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 51.NOVARTIS: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 52.PFIZER: NET SALES, 20182020 ($MILLION)
FIGURE 53.PFIZER: REVENUE SHARE, BY REGION, 2020 (%)
